Skip to main content
. 2025 Feb 3;64(3):373–385. doi: 10.1007/s40262-025-01473-9

Fig. 5.

Fig. 5

PBPK simulations of fasted PK profiles of efavirenz (a, b) and digoxin (c, d). a Efavirenz 600 mg oral administration simulated with measured FaSSIF solubility. b Efavirenz 600 mg oral administration simulated with optimized (red line) and maximum solubility (blue line). c Digoxin 1 mg oral administration simulated with measured FaSSIF solubility. d Digoxin 1 mg oral administration simulated with optimized (red line) and maximum solubility (blue line), in this case, overlapped. FaSSIF fasted state simulated intestinal fluid.